# Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen

> **NCT04839965** · PHASE2 · TERMINATED · sponsor: **Ampio Pharmaceuticals. Inc.** · enrollment: 36 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Ampion
- **OTHER:** Saline

## Key facts

- **NCT ID:** NCT04839965
- **Lead sponsor:** Ampio Pharmaceuticals. Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-05
- **Primary completion:** 2022-02-07
- **Final completion:** 2022-04-04
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** The AP-017 study was prematurely terminated by the sponsor after an interim analysis.
- **Last updated:** 2022-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04839965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04839965, "Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04839965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*